Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines

Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs

(2021) Stanislav Pantelyushin et al.   Cancers

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma

(2021) Naoya Maekawa et al.   npj Precision Oncology

Characterizing the molecular and immune landscape of canine bladder cancer

(2021) Kathryn E. Cronise et al.   Veterinary and Comparative Oncology

A Role for Dogs in Advancing Cancer Immunotherapy Research

(2020) Steven Dow   Frontiers in Immunology

Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy

(2020) Xiaodong Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy

(2019) Heng-Huan Lee et al.   CANCER CELL

Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway

(2019) Ning Pu et al.   CANCER LETTERS

PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition

(2019) Yilun Wu et al.   Frontiers in Immunology

The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy

(2019) Jiajing Cai et al.   OncoTargets and Therapy

Immune Responses in Bladder Cancer-Role of Immune Cell Populations, Prognostic Factors and Therapeutic Implications

(2019) Magdalene Joseph et al.   Frontiers in Oncology

PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer

(2018) David Stenehjem et al.   OncoTargets and Therapy

Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy

(2018) Han Yao et al.   Frontiers in Immunology

Bladder Preservation Therapy: Review of Literature and Future Directions of Trimodal Therapy

(2018) Adnan El-Achkar et al.   Current Urology Reports

Programmed cell death-1 (PD-1) checkpoint blockade in combination with a mammalian target of rapamycin inhibitor restrains hepatocellular carcinoma growth induced by hepatoma cell-intrinsic PD-1

(2017) Hui Li et al.   HEPATOLOGY

Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic

(2017) Girish S. Kulkarni et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

(2017) Padmanee Sharma et al.   LANCET ONCOLOGY

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

PD-1 and PD-L1 expression in bone and soft tissue sarcomas

(2017) Alireza Torabi et al.   PATHOLOGY

Programmed death ligand 1 is expressed in canine B cell lymphoma and downregulated by MEK inhibitors

(2017) S. R. Kumar et al.   Veterinary and Comparative Oncology

A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma

(2017) Naoya Maekawa et al.   Scientific Reports

Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer

(2016) Christophe Massard et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Immune regulation of canine tumour and macrophage PD-L1 expression

(2016) G. Hartley et al.   Veterinary and Comparative Oncology

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants

(2016) Subrata Chowdhury et al.   Oncotarget

Evaluation of Costimulatory Molecules in Peripheral Blood Lymphocytes of Canine Patients with Histiocytic Sarcoma

(2016) Michihito Tagawa et al.   PLoS One

PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells

(2015) K. M. Mahoney et al.   Cancer Immunology Research

Urinary Bladder Cancer in Dogs, a Naturally Occurring Model for Cancer Biology and Drug Development

(2014) D. W. Knapp et al.   ILAR JOURNAL

Expression of PD-L1 on Canine Tumor Cells and Enhancement of IFN-γ Production from Tumor-Infiltrating Cells by PD-L1 Blockade

(2014) Naoya Maekawa et al.   PLoS One

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE